Arca
Skip to content
Tools
Tools

TNFRSF10B: Tumor necrosis factor receptor superfamily member 10B

Receptor for the cytotoxic ligand TNFSF10/TRAIL.

  • Drugs that act on it: 7
  • Approved: 0
  • In phases 1 to 3: 7
  • Sponsors: 3

Who is on it, and how far along

Every drug ChEMBL records acting on TNFRSF10B, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Antibody 5
  • Protein or peptide 1
  • Other 1

Approved0

    Phase 31

    • Tigatuzumab

    Phase 25

    • Lexatumumab
    • Apomab
    • Conatumumab
    • Drozitumab
    • Dulanermin

    Phase 11

    • LBY-135

    Sponsors

    Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

    The landscape

    Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Tumor necrosis factor receptor superfamily member 10B agonist.
    TigatuzumabPhase 3Daiichi SankyoAntibodyAgonist0
    LexatumumabPhase 2—AntibodyAgonist11
    ApomabPhase 2—AntibodyAgonist0
    ConatumumabPhase 2AmgenAntibodyAgonist0
    DrozitumabPhase 2RocheAntibodyAgonist0
    DulanerminPhase 2RocheProtein or peptideAgonist0
    LBY-135Phase 1—OtherAgonist0

    Open trials

    The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 8 in all, from ClinicalTrials.gov.
    Futibatinib With Paclitaxel and Ramucirumab for the Treatment of Locally Advanced or Unresectable Gastric, Gastroesophageal Junction, or Esophageal AdenocarcinomaLexatumumabPhase 1RecruitingNorthwestern UniversityMay 18, 2026
    Nab-Paclitaxel PIPAC in Combination With Paclitaxel and Ramucirumab for the Treatment of Stomach Cancer With Peritoneal MetastasesLexatumumabPhase 1RecruitingCity of Hope Medical CenterNov 5, 2024
    Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)LexatumumabPhase 2 / Phase 3RecruitingSWOG Cancer Research NetworkSep 27, 2024
    Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE TrialLexatumumabPhase 2 / Phase 3RecruitingNational Cancer Institute (NCI)Jan 12, 2024
    Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)LexatumumabPhase 2RecruitingSWOG Cancer Research NetworkSep 11, 2023
    Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)LexatumumabPhase 2RecruitingSWOG Cancer Research NetworkDec 8, 2022
    Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)LexatumumabPhase 2 / Phase 3Active, not recruitingSWOG Cancer Research NetworkOct 27, 2021
    Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction CancerLexatumumabPhase 2Active, not recruitingAcademic and Community Cancer Research UnitedDec 9, 2020

    Diseases most associated with it

    Open Targets association score, 0 to 1; all associations
    • Basal cell carcinoma0.51
    • Head and neck squamous cell carcinoma0.46
    • Renal carcinoma0.44
    • Clear cell renal carcinoma0.42
    • Prostate carcinoma0.37
    • Abnormality of the skeletal system0.37
    • Vascular disorder0.36
    • Intestinal disorder0.35
    • Non-melanoma skin carcinoma0.33

    Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL1075153, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt O14763, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

    Esc

    Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

    Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.